WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 150 fonti internazionali, con classificazione AI e timeline cluster su singole storie.

Navigazione

Home
Archivio
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

FDA approves Hepcludex for chronic hepatitis D — Warptech Lab News

FDA approves Hepcludex for chronic hepatitis D

The FDA approved Hepcludex injection for the treatment of chronic hepatitis D infection in adults without cirrhosis or with compensated cirrhosis, according to a press release. Hepcludex (bulevirtide-gmod, Gilead Sciences) is the first FDA-approved treatment for the condition.

venerdì 22 maggio 2026 New tab

399 words~2 min read

May 22, 2026

1 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Other newsrooms on this story

· 3 sources

Full timeline →

morningstar.com·May 22, 2026 · 3 h fa
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
endpoints.news·May 22, 2026 · 2 h fa
FDA clears Gilead's hepatitis D drug, four years after prior rejection
morningstar.com·May 22, 2026 · 9 h fa
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

Related reading

morningstar.com

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the…

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic…

morningstar.com·3 h fa

FDA clears Gilead's hepatitis D drug, four years after prior rejection

Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues…

endpoints.news·2 h fa

US approves Gilead’s twice-yearly shot for HIV prevention

Lenacapavir was nearly 100 per cent effective in preventing HIV in clinical trials.

scmp.com·11 mesi fa

FDA approves Gilead's twice-yearly HIV prevention injection, offering a…

The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for…

cnbc.com·11 mesi fa

FDA approves new twice-yearly HIV shot. What to know

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show…

usatoday.com·11 mesi fa

FDA approves long-lasting HIV-prevention drug - UPI.com

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and…

upi.com·11 mesi fa